STOK

Stoke Therapeutics Inc

26.29

Oct 30 • 3:59 PM ET -0.06 (-0.23%)

27.00

Aftermarket • 5:00 PM ET +0.71 (2.70%)

Healthcare Biotechnology USA Small NASD

Oct 29, 4:11 PMStoke Therapeutics beats Q3 2026 revenue estimates with $11.3M (+6% YoY) and cash runway into early 2028

Peers: PRAX HRMY XENE IONS JAZZ RAPP WVE NGNE TSHA NBIX

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO DFAS TCAF

Scroll to Statements

Index	RUT
Market Cap	1.70B
Enterprise Value	1.38B
Income	-243.20M
Sales	28.21M
Book/sh	5.44
Cash/sh	4.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	170
IPO	Jun 19, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	60.13
P/B	4.83
P/C	5.31
P/FCF	-
EV/EBITDA	-
EV/Sales	48.91
Quick Ratio	7.69
Current Ratio	7.24
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.80
EPS next Y	-3.83
EPS next Q	-1.09
EPS this Y	-3107.97%
EPS next Y	0.48%
EPS next 5Y	-
EPS past 3/5Y	64.49% 40.50%
Sales past 3/5Y	145.89% -
EPS Y/Y TTM	-476.63%
Sales Y/Y TTM	-86.28%
EPS Q/Q	-64.63%
Sales Q/Q	5.86%
Earnings	Oct 29 AMC
EPS/Sales Surpr.	-16.24% 37.06%

Insider Own	17.10%
Insider Trans	-0.43%
Inst Own	113.45%
Inst Trans	9.45%
ROA	-63.42%
ROE	-73.62%
ROIC	-70.21%
Gross Margin	82.80%
Oper. Margin	-913.12%
Profit Margin	-862.07%
SMA20	5.19%
SMA50	-4.15%
SMA200	-14.97%
Trades

Shs Outstand	64.81M
Shs Float	53.49M
Short Float	19.18%
Short Ratio	10.02
Short Interest	10.26M
52W High	40.22 -34.63%
52W Low	20.32 29.38%
Volatility	4.06% 5.07%
ATR (14)	1.22
RSI (14)	52.31
Beta	1.36
Rel Volume	1.81
Avg Volume	1.02M
Volume	1,855,440

Perf Week	4.99%
Perf Month	1.08%
Perf Quarter	-11.06%
Perf Half Y	-20.53%
Perf YTD	-17.17%
Perf Year	-17.07%
Perf 3Y	636.41%
Perf 5Y	15.16%
Perf 10Y	-
Recom	1.00
Target Price	46.38
Prev Close	26.35
Price	26.29
Change %	-0.23%

Consensus

Strong Buy

Avg. Price Target

$46.38

Implied Upside

+76.4%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 21, 2026	Resumed	JJP Morgan	Overweight	$40	+52.1%
Jul 13, 2026	Initiated	GGoldman	Buy	$44	+67.4%
Feb 24, 2026	Initiated	WWolfe Research	Outperform	$40	+52.1%
Feb 05, 2026	Initiated	GGuggenheim	Buy	$60	+128.2%
Jan 05, 2026	Resumed	CChardan Capital Markets	Buy	$35	+33.1%
Jul 18, 2025	Initiated	JJefferies	Buy	$30	+14.1%
Dec 20, 2024	Initiated	CChardan Capital Markets	Buy	$24	-8.7%
Oct 14, 2024	Resumed	LLeerink Partners	Outperform	$18	-31.5%
Mar 26, 2024	Upgrade	TTD Cowen	Market Perform → Outperform
Nov 20, 2023	Resumed	JJP Morgan	Neutral
Jul 25, 2023	Downgrade	TTD Cowen	Outperform → Market Perform
May 01, 2023	Upgrade	BBofA Securities	Underperform → Neutral	$9 → $12	-54.4%
Apr 26, 2023	Resumed	CCanaccord Genuity	Buy	$24	-8.7%
Jan 06, 2023	Downgrade	BBofA Securities	Buy → Underperform	$22 → $9	-65.8%
Oct 24, 2022	Upgrade	SSVB Leerink	Mkt Perform → Outperform	$30	+14.1%
Jan 31, 2022	Initiated	JJefferies	Buy	$50	+90.2%
Dec 03, 2021	Initiated	BBofA Securities	Buy	$43	+63.6%
Nov 22, 2021	Upgrade	JJP Morgan	Neutral → Overweight	$41	+56.0%
May 18, 2021	Initiated	UUBS	Neutral	$35	+33.1%
May 10, 2021	Upgrade	WWedbush	Neutral → Outperform

Today 07:39AM	Stoke Therapeutics Misses On Launch-Driven Spending, But FDA Endpoint Deal Strengthens The Zorevunersen Case As Cash Runway Tightens (Earnings Whispers)
Oct-29-26 04:01PM	Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
Oct-22-26 10:40AM	Stoke's FDA Pre-NDA Outcome, Not Its Quarterly Loss, Is The Real Test For Shareholders (Earnings Whispers)
08:00AM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates (Business Wire)
Oct-16-26 04:20PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
08:00AM	Loading…
Oct-12-26 08:00AM	Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting (Business Wire)
Sep-23-26 04:01PM	Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization (Business Wire) -10.58%
Sep-16-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Sep-02-26 08:00AM	Stoke Therapeutics to Present at the Cantor Global Healthcare Conference (Business Wire)
Sep-01-26 10:00AM	Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress (InvestorsHub)
Aug-21-26 05:53AM	Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating (InvestorsHub)
Aug-18-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-05-26 08:00AM	Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
Aug-04-26 01:07AM	Stoke Therapeutics Inc (STOK) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) +7.14%
Aug-03-26 04:01PM	Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
04:01PM	Loading…
Jul-27-26 04:01PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates (Business Wire)
Jul-16-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-13-26 07:30AM	Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer (Business Wire) -6.12%
Jun-16-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
May-28-26 04:01PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire)
May-18-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
May-07-26 04:01PM	Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
Apr-30-26 04:01PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates (Business Wire)
Apr-16-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +5.46%
Apr-08-26 04:01PM	Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-07-26 04:01PM	Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors (Business Wire)
Apr-01-26 01:15PM	Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets (BioPharma Dive)
Mar-17-26 05:12PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -5.63%
Mar-05-26 08:44AM	Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? (Zacks)
Mar-04-26 05:06PM	The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome (Business Wire)
12:58PM	Loading…
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-24-26 04:01PM	Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-23-26 12:59PM	This Rare Disease Biotech Name Teases Around A Buy Point (Investor's Business Daily) +5.66%
Feb-18-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +10.94%
Feb-15-26 10:03AM	Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit (MarketBeat)
Feb-11-26 07:30AM	Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Feb-04-26 04:01PM	Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire) -5.30%
Jan-27-26 02:05PM	Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA (PR Newswire)
Jan-16-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-11-26 02:00PM	Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome (Business Wire)
Jan-06-26 04:01PM	Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +8.20%
Dec-16-25 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
01:16PM	Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% (Investor's Business Daily)
Dec-01-25 07:30AM	Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-18-25 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +7.31%
Nov-17-25 07:30AM	Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments (Business Wire)
Nov-05-25 04:01PM	Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference (Business Wire) -9.94%
12:00PM	All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy (Zacks)
12:05AM	Stoke Therapeutics Inc (STOK) Q3 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Nov-04-25 06:00PM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-30-25 04:30PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates (Business Wire) -5.24%
Oct-20-25 07:30AM	Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Oct-19-25 03:09AM	H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK) (Insider Monkey)
Oct-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Oct-10-25 10:06AM	Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Oct-09-25 04:30PM	Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
09:25AM	Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 07:30AM	Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer (Business Wire)
06:07AM	Gilead delays arrival of Biktarvy copycats; CDC updates vaccine schedule (BioPharma Dive)
Sep-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Sep-05-25 04:16PM	ZoomInfo, International Money Express, and More Stocks See Action From Activist Investors (Barrons.com) +5.35% +6.33%
Sep-02-25 07:00AM	Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
Aug-28-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 (Business Wire)
Aug-25-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (Business Wire)
Aug-18-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-13-25 03:12AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... (GuruFocus.com) +24.98%
Aug-12-25 05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
06:38AM	First patient dosed in Phase III trial of zorevunersen for Dravet syndrome (Clinical Trials Arena)
Aug-11-25 09:26AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:00AM	Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (GlobeNewswire)
Aug-07-25 07:00AM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates (Business Wire)
Aug-06-25 04:30PM	Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Aug-05-25 06:35PM	Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 10:17AM	Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug (Investing.com) +7.04%
Jul-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-10-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (GlobeNewswire)
Jun-17-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-25 07:30AM	Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-16-25 09:55AM	Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet (Zacks)
May-13-25 09:50AM	Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates (Zacks) -7.56%
07:00AM	Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
May-12-25 06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-01-25 12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:28AM	Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? (Investor's Business Daily)
06:45AM	Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar (Investor's Business Daily)
Apr-28-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-25 06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-22-25 12:00PM	Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.08%
04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-01-25 04:30PM	Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -6.32% +5.94%
Mar-18-25 12:40PM	Stoke Therapeutics Stock Slips as CEO Steps Down (Investopedia)
12:40PM	Stoke Therapeutics Slips as CEO Steps Down (Investopedia)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EDWARD KAYE	Former Affiliate	Oct 21 '26	Proposed Sale	25.68	1,496,042	38,418,359		Oct 21 04:42 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Oct 02 '26	Sale	26.33	627	16,509	20,598	Oct 02 05:37 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '26	Sale	26.16	1,051	27,494	19,059	Oct 02 05:35 PM
JONATHAN D ALLAN	Officer	Oct 02 '26	Proposed Sale	26.01	627	16,308		Oct 02 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 01 '26	Sale	30.67	5,545	170,061	20,110	Sep 03 04:17 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 14 '26	Option Exercise	0.00	10,000	0	30,422	Aug 18 08:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 18 '26	Sale	32.03	4,767	152,690	25,655	Aug 18 08:29 PM
Kaye Edward M. MD	Director	Aug 14 '26	Option Exercise	0.00	26,250	0	137,124	Aug 18 08:28 PM
Kaye Edward M. MD	Director	Aug 18 '26	Sale	32.03	12,567	402,528	124,557	Aug 18 08:28 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 14 '26	Option Exercise	0.00	6,000	0	24,086	Aug 18 08:27 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 18 '26	Sale	32.03	2,861	91,639	21,225	Aug 18 08:27 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 03 '26	Sale	29.04	7,176	208,385	20,422	Aug 05 04:17 PM
BARUCH TICHO	Officer	Aug 03 '26	Proposed Sale	28.86	20,967	605,108		Aug 03 04:48 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '26	Sale	32.66	7,228	236,068	27,598	Jul 06 04:10 PM
BARUCH S. TICHO	Officer	Jul 01 '26	Proposed Sale	32.72	7,228	236,500		Jul 01 04:51 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Jun 16 '26	Sale	29.95	1,457	43,637	18,086	Jun 18 04:18 PM
JONATHAN D ALLAN	Officer	Jun 16 '26	Proposed Sale	30.00	1,457	43,710		Jun 16 04:33 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 01 '26	Sale	30.58	1,795	54,891	34,826	Jun 03 05:33 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '26	Sale	32.79	2,243	73,548	36,621	May 05 04:18 PM
BARUCH S. TICHO	Officer	May 01 '26	Proposed Sale	32.72	4,038	132,123		May 01 04:44 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '26	Sale	32.66	1,838	60,029	38,864	Apr 03 04:12 PM
BARUCH S. TICHO	Officer	Apr 01 '26	Proposed Sale	32.56	1,838	59,845		Apr 01 04:39 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 20 '26	Sale	33.69	9,293	313,038	19,543	Mar 24 04:19 PM
JONATHAN ALLAN	Officer	Mar 20 '26	Proposed Sale	33.19	9,293	308,435		Mar 20 04:33 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Option Exercise	2.19	1,365	2,989	42,163	Mar 19 06:01 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 18 '26	Sale	31.34	6,686	209,569	40,798	Mar 19 06:01 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 17 '26	Sale	33.01	6,164	203,451	47,484	Mar 19 06:01 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Sale	29.99	1,461	43,815	40,702	Mar 19 06:01 PM
Leggett Thomas	Chief Financial Officer	Mar 18 '26	Sale	31.34	2,382	74,663	10,172	Mar 19 06:00 PM
Leggett Thomas	Chief Financial Officer	Mar 17 '26	Sale	33.01	2,196	72,482	12,554	Mar 19 06:00 PM
Hoitt Jason	Chief Patient Officer	Mar 18 '26	Sale	31.34	1,931	60,526	10,276	Mar 19 05:58 PM
Hoitt Jason	Chief Patient Officer	Mar 17 '26	Sale	33.01	1,781	58,785	12,207	Mar 19 05:58 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 18 '26	Sale	31.34	4,628	145,063	28,836	Mar 19 05:57 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 17 '26	Sale	33.01	4,267	140,838	33,464	Mar 19 05:57 PM
BARUCH S. TICHO	Officer	Mar 19 '26	Proposed Sale	31.02	1,461	45,320		Mar 19 04:19 PM
Hoitt Jason	Chief Patient Officer	Mar 15 '26	Option Exercise	0.00	10,000	0	13,988	Mar 17 05:26 PM
Leggett Thomas	Chief Financial Officer	Mar 15 '26	Option Exercise	0.00	14,750	0	14,750	Mar 17 05:26 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '26	Option Exercise	0.00	33,850	0	53,648	Mar 17 05:25 PM
Kaye Edward M. MD	Director	Mar 15 '26	Option Exercise	0.00	61,750	0	110,874	Mar 17 05:24 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '26	Option Exercise	0.00	25,475	0	37,731	Mar 17 05:23 PM
LEVIN ARTHUR A	Director	Mar 13 '26	Sale	36.80	605	22,264	4,237	Mar 17 05:23 PM
ARTHUR A LEVIN	Director	Mar 13 '26	Proposed Sale	36.48	605	22,070		Mar 13 04:19 PM
TZIANABOS ARTHUR	Interim Executive Chair	Mar 10 '26	Option Exercise	8.33	3,955	32,945	35,694	Mar 12 04:57 PM
TZIANABOS ARTHUR	Interim Executive Chair	Mar 10 '26	Sale	40.00	4,355	174,214	31,339	Mar 12 04:57 PM
Krainer Adrian R.	Director	Mar 10 '26	Sale	39.74	33,243	1,320,964	283,302	Mar 12 04:56 PM
ARTHUR TZIANABOS	Director	Mar 10 '26	Proposed Sale	38.31	90,508	3,467,361		Mar 10 04:39 PM
Krainer Adrian R.	Director	Mar 02 '26	Sale	39.66	7,229	286,715	316,545	Mar 04 04:28 PM
Adrian Krainer	Director	Mar 02 '26	Proposed Sale	36.41	40,472	1,473,586		Mar 02 04:42 PM
LEVIN ARTHUR A	Director	Dec 31 '25	Option Exercise	0.00	1,211	0	4,842	Jan 05 04:16 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 08 '25	Sale	32.28	3,978	128,411	11,831	Dec 10 04:24 PM
Kaye Edward M. MD	Director	Dec 08 '25	Sale	32.27	13,430	433,385	49,124	Dec 10 04:23 PM
EDWARD M KAYE	Director	Dec 08 '25	Proposed Sale	30.87	13,430	414,584		Dec 08 04:40 PM
JONATHAN ALLAN	Officer	Dec 08 '25	Proposed Sale	30.87	3,978	122,801		Dec 08 04:38 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '25	Option Exercise	0.00	10,000	0	25,156	Dec 05 08:51 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 05 '25	Sale	31.34	3,662	114,762	19,798	Dec 05 08:51 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 04 '25	Sale	30.87	1,696	52,353	23,460	Dec 05 08:51 PM
Kaye Edward M. MD	Director	Dec 03 '25	Option Exercise	0.00	26,250	0	77,555	Dec 05 08:50 PM
Kaye Edward M. MD	Director	Dec 05 '25	Sale	31.32	8,548	267,761	62,554	Dec 05 08:50 PM
Kaye Edward M. MD	Director	Dec 04 '25	Sale	30.87	6,453	199,197	71,102	Dec 05 08:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '25	Option Exercise	0.00	6,000	0	25,612	Dec 05 08:49 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 05 '25	Sale	31.29	8,785	274,898	15,809	Dec 05 08:49 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 04 '25	Sale	30.87	1,018	31,425	24,594	Dec 05 08:49 PM
EDWARD M KAYE	Director	Dec 05 '25	Proposed Sale	31.05	2,181	67,720		Dec 05 04:38 PM
JONATHAN ALLAN	Officer	Dec 05 '25	Proposed Sale	31.05	7,781	241,600		Dec 05 04:29 PM
BARUCH TICHO	Officer	Dec 05 '25	Proposed Sale	31.05	1,989	61,758		Dec 05 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 01 '25	Option Exercise	0.00	11,981	0	19,176	Dec 03 08:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '25	Sale	30.65	2,014	61,725	15,156	Dec 03 08:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '25	Sale	29.78	2,006	59,743	17,170	Dec 03 08:23 PM
Kaye Edward M. MD	Director	Dec 03 '25	Sale	30.65	1,070	32,793	51,305	Dec 03 08:22 PM
Kaye Edward M. MD	Director	Dec 02 '25	Sale	29.78	1,066	31,748	52,375	Dec 03 08:22 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 01 '25	Option Exercise	0.00	12,357	0	24,188	Dec 03 08:20 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '25	Sale	30.65	2,292	70,245	19,612	Dec 03 08:20 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 02 '25	Sale	29.78	2,284	68,023	21,904	Dec 03 08:20 PM
Krainer Adrian R.	Director	Nov 24 '25	Sale	29.72	40,472	1,202,719	323,774	Nov 26 04:06 PM
Adrian Krainer	Director	Nov 24 '25	Proposed Sale	29.34	40,472	1,187,448		Nov 24 04:24 PM
Krainer Adrian R.	Director	Nov 14 '25	Sale	26.98	40,472	1,092,058	364,246	Nov 18 04:22 PM
Adrian Krainer	Director	Nov 14 '25	Proposed Sale	26.07	40,472	1,055,105		Nov 14 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 03 '25	Sale	25.72	5,931	152,566	7,195	Nov 05 04:20 PM
BARUCH TICHO	Officer	Nov 03 '25	Proposed Sale	30.04	5,931	178,167		Nov 03 04:22 PM

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

C.P.A.Mr. Ian F. Smith A.C.A.

Co-Founder & Independent DirectorDr. Adrian R. Krainer Ph.D.

Chief Financial OfficerMr. Thomas Edward Leggett

Chief Patient OfficerMr. Jason Hoitt

Co-Founder & CTOMs. Isabel Aznarez Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STOK

Stoke Therapeutics Inc

Upgrade your Finviz experience